Businesses around the world are shifting into overdrive to help battle the coronavirus, providing everything from rubber gloves and ventilators to diagnostic tools and, hopefully soon, vaccines. While the pandemic continues to wreak havoc, large corporations and small businesses are developing creative solutions to halt the spread of the virus.
Just as automakers famously shifted to make tanks and planes during World War II, today’s global giants — LVMH, Ford and GE to name a few — are retooling their production lines to help make everything from hand sanitizers to respirators. On the medical front, there are more than three dozen Covid-19 vaccines under development, a smart move considering that two out of every three vaccines for infectious diseases fail, according to a study by the Massachusetts Institute of Technology.
Forbes will continue to update this list of private companies and how they are stepping up to fight the Covid-19 pandemic:
Abbott Laboratories: Abbott Park, Illinois healthcare firm obtained emergency authorization from the U.S. Food and Drug Administration (FDA) for its 5-minute coronavirus testing kit on March 27; it is now manufacturing 50,000 kits a day with plans to expand to 2 million kits a month by June. The company’s new Covid-19 antibody test, which gained FDA approval on April 26, won a contract to supply the Italian government with four million tests by the end of May.
Alphabet: Through its healthcare arm Verily, Google’s parent company launcheda website where users can find nearby testing sites at 90 locations in thirteen U.S. states.
Aytu BioScience: Colorado-based pharmaceutical company launched a rapid blood test that can detect Covid-19 antibodies in the blood within two to ten minutes, with a first shipment of 2,750 tests delivered to the Denver police department.
Ava: Swiss medical bracelet manufacturer, which makes a device that tracks women’s fertility, is partnering with the Lichenstein government for a Covid-19 early detection program. In the initial phase, Ava will provide bracelets to 2,000 individuals and monitor them for potential coronavirus symptoms. A second phase will extend the program to all of Liechtenstein’s 39,000 residents.
Biobot Analytics: Somerville, Massachusetts wastewater epidemiology firm — originally a spin-off from the Massachusetts Institute of Technology — is workingwith researchers at MIT and Harvard to track the spread of Covid-19 by analyzing sewage samples from wastewater treatment facilities.
BioIQ: Atlanta-based healthcare firm announced a new, FDA-approved saliva test for Covid-19 — an alternative to the common nasal swab — on March 31.
BioMérieux: French biotech company, founded by billionaire Alain Mérieux, received emergency FDA approval for its subsidiary’s new testing kit, which cuts testing times for the virus down to 45 minutes.
Camtech Diagnostics: Singapore-based biotech company, founded by Dr. Kuok Meng Han — the son of palm oil billionaire Kuok Khoon Hong — is making rapid antibody testing kits for Covid-19 and distributing them to hospitals in Singapore, Indonesia, the Philippines, Malaysia and China.
Cellex: North Carolina biopharma firm’s antibody-based test for Covid-19 received emergency approval from the FDA.
Cepheid: Sunnyvale, California molecular diagnostics company gainedemergency FDA authorization for its new 45-minute Covid-19 testing kit.
Copan Diagnostics: Family-owned company located at the heart of Italy’s hard-hit Lombardy region makes diagnostic swabs for testing, airlifting 500,000 swabs to the U.S.
Credo Diagnostics: Singapore-based biomedical firm developed a new 20-minute coronavirus testing kit, which has been approved by European regulators and will be distributed by Italian pharma company Menarini.
CVS Health: Healthcare giant plans to start offering self-swab diagnostic tests for Covid-19 at up to 1,000 of its U.S. stores in May. The patients schedule the tests online, then collect the kits at the testing sites and self-swab, before returning the kits for results.
DiaSorin: Italian biotech company owned by billionaire Gustavo Denegriobtained emergency authorization from the FDA in March for its new 60-minute Covid-19 testing kit. On April 7, it announced a serology test that can detect the presence of Covid-19 antibodies in the blood, which received FDA authorization on April 24. The firm is now providing the tests to authorities in Belgium, Germany, Israel and at least three Italian regions.
Diesse Diagnostica Senese: Siena, Italy diagnostics outfit is making 1.2 million Covid-19 antibody tests a week and provided 500,000 of these tests to the Italian region of Tuscany.
Henry Schein: New York-based medical supplier announced on March 26 it would begin distributing a new 15-minute blood test for Covid-19 antibodies, produced by South Korean diagnostic firm SD Biosensor, in the U.S.
Ipsum Diagnostics: Sandy Springs, Georgia diagnostic company gainedemergency FDA authorization for its Covid-19 testing kit.
Mammoth Biosciences: South San Francisco-based biotech startup, founded by three 30 Under 30 alums, prototyped a rapid test by using the gene-editing tool Crispr to detect the disease.
Mesa Biotech: San Diego biotech business obtained FDA approval for its new 30-minute testing kit for Covid-19.
Puritan Medical Products: Maine-based diagnostic maker, one of the world’s largest makers of diagnostic swabs along with Italy’s Copan Diagnostics, is reportedly increasing production to make one million Covid-19 testing swabs a week.
QIAGEN: Hilden, Germany-based molecular diagnostics firm receivedemergency approval from the FDA for its new Covid-19 testing kit.
Rite Aid: Drugstore chain is offering self-swab testing sites at 25 stores in eight U.S. states, in partnership with the U.S. Department of Health and Human Services.
Sherlock Biosciences: Cambridge, Massachusetts diagnostics firm receivedFDA approval for its Covid-19 diagnostic test, which uses the gene-editing technology Crispr to provide results in about an hour.
Siemens Healthineers: The German conglomerate’s healthcare unit receivedFDA clearance for its blood gas analyzer, which helps doctors monitor the conditions of critical Covid-19 patients in ICUs.
Walgreens Boots Alliance: Drugstore giant, led by Italian billionaire Stefano Pessina, is offering drive-thru rapid diagnostic tests in twelve U.S. states and expects to start testing more than 50,000 people a week in the U.S.
4D Pharma: Leeds, UK pharmaceutical outfit received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to begin phase two trials of MRx-4DP0004 — a live microorganism product that the company was originally developing to treat asthma — on up to 90 Covid-19 patients.
AbbVie: North Chicago-based, publicly traded pharma firm is collaborating with authorities in the EU, the U.S. and China on experimental use of its HIV drug lopinavir/ritonavir to treat Covid-19; results from two clinical trials published in March and April found the drug to be ineffective against the disease.
AIM Immunotech: Florida-based pharmaceutical company announced on March 9 it would begin experimental testing of its chronic fatigue syndrome drug rintatolimod as a treatment for Covid-19 in Japan, at the National Institute of Infectious Diseases and the University of Tokyo.
Aldeyra Therapeutics: Lexington, Massachusetts biotech company announcedpositive results from phase one clinical trials of its autoimmune disease drug ADX-629 on Covid-19 patients on April 14; the firm is now planning phase two trials.
Alexion Pharmaceuticals: The Boston firm is planning phase three clinical trials of its PNH blood disease drug ravulizumab-cwvz on 270 Covid-19 patients in multiple countries.
AlloVir: Houston-based cell and gene therapy company is collaborating with Baylor College of Medicine to discover and develop T-cell therapies to fight Covid-19.
Amgen: Thousand Oaks, California biotech outfit is working with Seattle-based Adaptive Technologies to develop antibody-based treatments for Covid-19.
Ampio Pharmaceuticals: Englewood, Colorado biopharma company is studying the use of a nebulized form of its osteoarthritis drug Ampion as a treatment against Covid-19.
Ansun Biopharma: On April 2, the San Diego-based biopharma company announced “highly encouraging” preliminary results from a trial of its antiviral drug DAS181 on four Covid-19 patients at the Renmin Hospital of Wuhan University. After two weeks, the first two patients no longer required supplemental oxygen, and a third patient became virus-free after 10 days of treatment. On April 15, the firm initiated clinical trials of DAS181 on 22 patients in the U.S., with plans to expand to 60 more patients in the U.S. and Europe.
Apeiron Biologics: Vienna, Austria-based biotech firm announced it would begin a trial of its immunotherapy treatment on 200 Covid-19 patients in Austria, Germany and Denmark.
Apeptico: Vienna-based biotech company received approval from Austrian regulators to begin trials of its pulmonary dysfunction drug solnatide on Covid-19 patients under a compassionate use program.
Applied Therapeutics: New York-based biopharma outfit is conducting trials of its lung inflammation and cardiomyopathy drug, AT-001, on Covid-19 patients at several hospitals in New York City, including Mount Sinai.
ARMS Pharmaceutical: Ohio drugmaker is working with University Hospitals Cleveland on clinical trials of the investigational respiratory drug ARMS-I on Covid-19 patients in their home state.
Ascletis: Hangzhou, China pharmaceutical company announced results of clinical trials of its antiviral drug danoprevir on Covid-19 patients in China; the small-scale study found that “danoprevir combined with ritonavir is safe and well tolerated in all patients.”
AstraZeneca: British pharma giant is preparing larger clinical trials of its blood cancer drug Calquence on Covid-19 patients after small studies showed promising results. On May 21, the company received $1 billion in funding from the U.S. government for the production of a Covid-19 vaccine it’s developing with the Jenner Institute at the University of Oxford, which began human trials on April 22.
ATyr Pharma: San Diego-based biotherapeutics firm received FDA approval to begin phase two trials of its interstitial lung disease investigational drug, ATYR1923, on Covid-19 patients in the U.S.
Bausch Health: Canadian pharma giant initiated clinical trials of its respiratory tract infection treatment Virazole — a form of the antiviral medication ribavirin delivered by aerosol — on Covid-19 patients in Canada.
BeiGene: The Beijing-based biotech company is launching clinical trials of its mantle cell lymphoma drug zanubrutinib on 42 Covid-19 patients in the U.S. On April 29, the firm announced a collaboration with South San Francisco biopharma outfit Atreca and Mountain View, California-based IGM Biosciences to develop antibody-based treatments for Covid-19.
Bellerophon Therapeutics: New Jersey-based biotherapeutics firm receivedFDA approval for use of its nitric oxide delivery system INOpulse as a treatment for Covid-19.
BioCryst Pharmaceuticals: Durham, North Carolina-based pharmaceutical company started clinical trials of its antiviral drug galidesivir on Covid-19 patients in Brazil, with funding from the U.S. National Institute of Allergy and Infectious Diseases.
Biohaven Pharmaceuticals: New Haven, Connecticut pharmaceutical firm received FDA approval to begin clinical trials of its migraine drug vagezepant on Covid-19 patients.
Bukwang Pharmaceutical: Seoul, South Korea-based pharma outfit announced positive antiviral effects from trials of its hepatitis B drug clevudine on Covid-19 patients in South Korea.
CalciMedica: La Jolla, California-based biotech company started clinical trials of its pancreatitis drug CM4620-IE on Covid-19 patients at St. Paul, Minnesota’s Regions Hospital and Detroit’s Henry Ford Hospital.
Can-Fite: Israeli biotech outfit is testing its psoriasis drug piclidenoson to treat Covid-19 patients under a compassionate use program.
Capricor Therapeutics: Los Angeles-based biotech firm is providing its cell therapy drug CAP-1002 to Covid-19 patients in its home city under a compassionate use program.
Celltrion: South Korean healthcare firm is developing an antiviral treatment for Covid-19, with plans to start human trials in July; the company is also developing rapid self-testing kits that would provide results within fifteen to twenty minutes, expected by the summer.
Celularity: New Jersey-based therapeutics startup obtained FDA clearance to begin trials of a potential stem cell treatment against Covid-19.
Cocrystal Pharma: Bothell, Washington pharma outfit is developing antivirals to treat Covid-19 using patents it recently acquired from the Kansas State University Research Foundation.
CSL Behring: Pennsylvania biotherapeutics outfit is working with Sioux Falls, South Dakota-based SAB Therapeutics to start clinical trials of its antibody-based treatment SAB-185 on Covid-19 patients by the summer of 2020.
Cyclacel Pharmaceuticals: Berkeley Heights, New Jersey biopharma company is collaborating with the University of Edinburgh to study the use of its two IL-6 inhibitor drugs, fadraciclib and seliciclib, as a potential treatment for the disease.
CytoDyn: Vancouver, Washington biotech firm announced preliminary results from three days of testing its antiviral drug leronlimab on Covid-19 patients in New York; the company stated in a press release that “test results from the first four patients suggests immunological benefit within three days following treatment with leronlimab.”
Eiger Biopharmaceuticals: Palo Alto-based biopharma firm is supplying its hepatitis D drug peginterferon lambda to multiple studies testing the drug’s efficacy as a treatment for Covid-19 in the U.S. and other countries.
Eli Lilly: Indianapolis pharma company is partnering with Vancouver-based biotech outfit AbCellera to develop antibody-based treatments for Covid-19; on April 10, the company announced it would begin clinical trials of its rheumatoid arthritis drug baricitinib on Covid-19 patients in the U.S., with future tests expected in Europe and Asia. On May 4, Eli Lilly and Shanghai-based Junshi Biosciences announced an agreement to develop therapeutic antibodies to treat Covid-19.
Emergent BioSolutions: Maryland drugmaker received $14.5 million in funding from the U.S. Department of Health and Human Services (HHS) to develop treatments derived from the antibodies found in the blood of people who recovered from the disease.
EUSA Pharma: British pharmaceutical firm initiated trials of its siltuximab antibody treatment on Covid-19 patients at the Papa Giovanni XXIII hospital in Bergamo, Italy; the company released initial data on April 1 showing that one third of patients “experienced clinical improvement with reduced need for oxygen support” and a further 43% “saw their disease stabilise.”
Faron Pharmaceuticals: Turku, Finland-based drug developer receivedapproval from Finnish regulators to begin trials of its drug interferon beta-1a to treat Covid-19 patients in Europe, Asia and North America, excluding the U.S.
Fujifilm: Tokyo-based conglomerate’s pharmaceutical arm, Fujifilm Toyama Chemical, recently started phase three clinical trials of its flu drug favipiravir on Covid-19 patients in Japan and is accelerating production.
Gilead: The Californian biotech giant initiated clinical trials in March for its antiviral drug remdesivir on Covid-19 patients in the U.S. On April 29, the firm released preliminary results from its phase three trial, showing that Covid-19 patients treated with remdesivir recovered after an average of 11 days, compared to 15 days for patients receiving a placebo.
Green Cross: South Korean biopharma company is developing cell therapy-based treatments for Covid-19, with plans to begin human trials in the second half of 2020.
Grifols: Spanish pharmaceutical company is working with the FDA and the HHS to develop a Covid-19 treatment using the blood plasma of former patients.
Harbour BioMed: Cambridge, Massachusetts biomedical firm announced a collaboration with New York’s Mount Sinai Health System to develop new human antibodies to treat Covid-19.
Hope Biosciences: Houston-based stem cell therapy firm received FDA approval to start phase two clinical trials of its HB-adMSCs stem cell treatment in patients with Covid-19.
Humanigen: Burlingame, California pharma company received emergency FDA approval for compassionate use of its antibody lenzilumab in Covid-19 patients.
I-Mab Biopharma: Shanghai-based biopharma outfit announced it would begin clinical trials of its TJM2 antibody treatment on Covid-19 patients in the United States, with plans to expand to other countries affected by the pandemic.
Incyte: Delaware-based pharmaceutical firm is planning to begin phase three clinical trials of its myelofibrosis drug ruxolitinib on Covid-19 patients in the U.S.
InflaRx: German drugmaker is testing its IFX-1 antibody treatment on Covid-19 patients in the Netherlands; initial studies on patients in China drew positive results.
Innovation Pharmaceuticals: Wakefield, Massachusetts biopharma firm is researching the use of its drug brilacidin — part of a category of investigational new drugs called defensin mimetics, which could have antimicrobial effects — as both a treatment and a vaccine for Covid-19, in separate efforts with a “major U.S. university” and with the HHS.
ISR Immune System Regulation: Swedish immunotherapy firm’s subsidiary, ISR HBV, is conducting toxicological studies to determine whether its Immunolid ISR50 treatment could be used against Covid-19.
Kamada: Israeli pharmaceutical company is working on an antibody-based treatment for Covid-19 using the blood plasma of patients who recovered from the disease.
Karyopharm Therapeutics: Newton, Massachusetts pharmaceutical company is planning clinical trials of its anti-cancer drug selinexor to treat Covid-19 patients.
KD Pharma Group: Swiss drugmaker is working with SLA Pharma to start clinical trials of an oral version of the EPA-FFA fatty acid as a treatment for patients with Covid-19 in the UK.
Kiniksa Pharmaceuticals: Bermuda-based pharmaceutical outfit announcedpositive early results from tests of its anti-inflammatory drug mavrilimumab on Covid-19 patients in Italy; new trials are planned in both Italy and the U.S.
Laurent Pharmaceuticals: Montreal-based biopharma company is planning to begin phase two clinical trials of its cystic fibrosis drug LAU-7b (fenretide) as a treatment for Covid-19 on 200 patients in Canada and the U.S. by early May.
Livongo: San Francisco digital healthcare firm received emergency FDA authorization for the use of its remote blood glucose meter in hospitals, where the device will help doctors monitor the blood glucose levels of diabetic Covid-19 patients without having to physically enter their rooms.
Mateon Therapeutics: Californian biopharma firm is testing a number of antiviral drugs as potential treatments for Covid-19, including the anti-malarial drug artemisinin, and submitted an application to the FDA in order to begin clinical trials on patients.
Merck KGaA: Darmstadt, Germany-based pharma multinational donated a supply of its multiple sclerosis drug interferon beta-1a to the French National Institute of Health and Medical Research in Paris for clinical trials on Covid-19 patients. The company’s North American life sciences arm, MilliporeSigma, is supplying several vaccine efforts with reagents and other essential raw products for vaccine development.
Mesoblast: Australian medical firm is working with authorities in the U.S., Australia, China and Europe to evaluate the use of its remestemcel-L stem cell therapy to treat Covid-19. On April 24, the company announced results from a compassionate use program at New York City’s Mount Sinai Hospital, which showed that 83% of ventilator-dependent Covid-19 patients survived after two infusions of the drug. On April 29, Mesoblast announced it had begun enrolling up to 300 patients in a new clinical trial at more than 20 hospitals in the U.S.
Mylan: Pennsylvania-based pharmaceutical firm restarted production of hydroxychloroquine, a drug used to fight lupus, malaria and arthritis, at its West Virginia factory; the drug is being tested as a treatment for Covid-19 in human trials in New York.
OncoImmune: Maryland-based biopharma outfit received FDA approval to start clinical trials of its cancer drug CD24Fc on 230 patients with Covid-19.
Panoptes Pharma: Vienna, Austria biotech outfit is planning to begin trials of its eye disease drug PP-001 to treat Covid-19 patients; similar drugs, known as DHODH inhibitors, have shown promising results against Covid-19 in Wuhan, China.
Partner Therapeutics: Lexington, Massachusetts biotech startup began clinical trials of its bone marrow stimulant drug sargramostim on Covid-19 patients at University Hospital Ghent in Belgium.
Pfizer: The pharma titan is funding a study of its rheumatoid arthritis drug tofacitinib on Covid-19 patients in Italy.
PharmaMar: Spanish drugmaker is preparing to start clinical trials of its multiple myeloma drug plitidepsin to treat Covid-19 patients at several hospitals in Spain.
Pharming: Dutch medical firm announced “encouraging results” from five Covid-19 patients treated with its hereditary angioedema drug Ruconest under a compassionate use program at the University Hospital Basel in Switzerland.
Pluristem Therapeutics: Haifa, Israel-based medical company is developing a cell-based therapy to treat Covid-19, announcing on March 30 it had dosed three Israeli patients under a compassionate use program, with plans to enroll more.
Pulmotect: Houston-based biotech company announced positive results from animal trials of its respiratory drug PUL-042 as a treatment for Covid-19.
Regeneron Pharmaceuticals: Westchester, New York biotech outfit, run by billionaires Leonard Schleifer and George Yancopoulos, is conducting clinical trials of its rheumatoid arthritis drug sarilumab, developed with French firm Sanofi, on patients in New York.
Relief Therapeutics: Swiss drug developer partnered with Delaware-based NeuroRx to start clinical trials of its erectile dysfunction drug aviptadil on Covid-19 patients at Philadelphia’s Thomas Jefferson University Hospital.
Ridgeback Biotherapeutics: Miami-based biotech company received FDA approval to begin human trials of its antiviral drug EIDD-2801 — which it developed with the Atlanta-based Drug Innovations at Emory, a company owned by Emory University — on Covid-19 patients in the U.S; phase one trials in the UK began on April 10. On May 26, the firm announced an agreement with pharma multinational Merck to further develop the drug.
Roivant Sciences: Swiss pharma company is working with U.S. authorities to begin trials of its antibody treatment, gimsilumab, on Covid-19 patients.
Sarepta Therapeutics: The Cambridge, Massachusetts drug developer is partnering with the U.S. Army’s Medical Research Institute of Infectious Diseases to identify antisense oligonucleotides, a type of molecule which can be used to alter RNA, that could treat Covid-19.
Synairgen: Southampton, UK-based drugmaker began clinical trials of its SNG001 treatment on Covid-19 patients on March 31.
Takeda: Japanese medical firm partnered with Pennsylvania-based CSL Behring to create an alliance focused on hyperimmune therapy using blood plasma from previously infected Covid-19 patients. The alliance now includes eight other plasma companies.
Union Therapeutics: Copenhagen-based pharmaceutical firm is planning to test its dermatitis drug niclosamide on Covid-19 patients in partnership with the Institut Pasteur Korea, an infectious diseases research center in South Korea.
Vault Health: New York-based men’s health startup announced on April 14 it had developed an FDA-approved saliva test for Covid-19 in partnership with Rutgers University’s biomaterials bank RUCDR Infinite Biologics. Unlike the more common nasal swab tests, these saliva tests can be administered remotely. The patients can purchase a testing kit online for $150, complete the test with the help of a Vault Health technician via a Zoom video call, and then ship the test back to the RUCDR lab to receive results within 2-3 days.
Vir Biotechnology: The San Francisco-based firm is collaborating with a number of companies and institutions — Cambridge, Massachusetts-based biotech companies Biogen and Generation Bio; Chinese medical firm WuXi Biologics; Monrovia, California-based drugmaker Xencor; and the National Institutes of Health — to manufacture antibodies that could treat the virus; it’s also working with Massachusetts-based Alnylam Pharmaceuticals to develop RNA interference therapies. On April 6, British pharma giant GlaxoSmithKline purchased a stake in the company for $250 million, with the goal of collaborating on treatments for Covid-19.
XBiotech: Austin, Texas-based biopharma firm is working with the FDA and San Antonio-based nonprofit BioBridge Global to identify useful antibodies in the blood plasma of patients who have recovered from Covid-19.
Zhejiang Hisun Pharmaceuticals: Chinese pharmaceutical company announced positive results from trials of its flu drug favipiravir on Covid-19 patients in Shenzhen and Wuhan; the company is supplying the drug to authorities in China and several foreign countries.
Advent-Irbm: Pomezia, Italy-based pharmaceutical company is working with the Jenner Institute at the University of Oxford to develop a Covid-19 vaccine; clinical trials began on April 22, and the effort received nearly $53 million in funding from the British government.
AJ Vaccines: Danish vaccine developer is working on a Covid-19 vaccine that could hit the market in 2021.
Altimmune: The company is developing a novel intranasal vaccine for the coronavirus, making it one of three firms based in Gaithersburg, Maryland — along with Emergent Biosolutions and Novavax — that’s working on treatments and vaccines for Covid-19.
Arcturus Therapeutics: San Diego-based vaccine maker is developing a Covid-19 vaccine with researchers at the Duke-National University of Singapore medical school in Singapore.
Biocad: Russian drug developer is researching a Covid-19 vaccine, with animal trials scheduled for late April.
BioNTech: German biotech firm backed by billionaire twins Thomas and Andreas Struengmann is working to develop a coronavirus vaccine in partnershipwith Pfizer and Fosun Pharma, chaired by Chinese billionaire Guo Guangchang. The company began human trials of the vaccine on April 23 in Germany and plans to expand them to the U.S. after receiving approval from regulators.
CanSino Biologics: Tianjin, China-based pharma company is beginning the second phase of clinical trials for its Covid-19 vaccine, using the vaccine technology deployed to develop the Ebola vaccine.
Cel-Sci Corp.: The biotech company is working with the University of Georgia on a Covid-19 vaccine, building on previous work for an H1N1 flu vaccine.
Codagenix: Melville, New York biotech firm is teaming up with the Serum Institute of India to develop a live-attenuated Covid-19 vaccine, which uses a live but weakened form of the virus.
CureVac: German firm, funded by billionaire Dietmar Hopp and the Bill and Melinda Gates Foundation, received $87 million from the European Commission to scale up development of its coronavirus vaccine.
Dyadic: Jupiter, Florida company is collaborating with the Israel Institute for Biological Research on both treatment and a vaccine against Covid-19, using the firm’s gene expression platform.
Dynavax: Emeryville, California vaccine maker is working with the Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Queensland to develop a Covid-19 vaccine.
EpiVax: Providence-based immunology firm is working on several Covid-19 vaccine candidates; its partners include with the University of Georgia, Belgian vaccine developer eTheRNA Immunotherapies and Miramar, Florida biotech outfit Generex and Maryland biotech firm Immunomic Therapeutics.
ExpreS2ion: Danish biotech company received a grant of nearly $1 million from the European Union to develop a vaccine for Covid-19.
FluGen: Madison, Wisconsin-based flu vaccine developer is working with India’s Bharat Biotech and virologists at the University of Wisconsin-Madison to develop a Covid-19 vaccine based on the company’s flu vaccine candidate.
GeneOne Life Science: South Korean vaccine maker is collaborating with researchers at the Houston Methodist Hospital to develop an RNA vaccine for Covid-19.
GeoVax: Atlanta-based medical company is collaborating with Wuhan-based BioVax to jointly produce a Covid-19 vaccine.
GlaxoSmithKline: British pharma titan is partnering with CEPI and Chengdu, China-based Clover Pharmaceuticals to use its pandemic vaccine adjuvant platform — which boosts the immune response in patients receiving a shot — to speed up development of Covid-19 vaccines; on April 6, the company purchased a stake in San Francisco-based Vir Biotechnology for $250 million, with the goal of collaborating on treatments for Covid-19.
Greenlight Biosciences: Boston-based RNA production company announced a $17 million funding round to boost its production capacity for making mRNA on May 12. The firm will use the money to produce a Covid-19 vaccine based on mRNA technology.
Greffex: Houston-based genetic engineering firm is preparing to begin animal trials for its Covid-19 vaccine.
Heat Biologics: North Carolina biopharma company is developing a Covid-19 vaccine with the University of Miami.
iBio: Newark, Delaware biotech upstart is collaborating with Beijing-based CC-Pharming on the rapid development of a Covid-19 vaccine.
IMV: Canadian biopharma company will start animal testing of its Covid-19 vaccine candidate in April and May, with plans for human trials in Nova Scotia and Quebec.
Inovio: Plymouth Meeting, Pennsylvania biotech business is the second company to start human trials of a Covid-19 vaccine, announcing on April 6 it would begin testing in Philadelphia and Kansas City; the company also received $11.9 million in funding from the Department of Defense to rapidly produce the vaccine.
Johnson & Johnson: The company’s pharma unit, Janssen, will start manufacturing its vaccine — developed with the HHS — this month, with human trials set to begin by September and a public rollout hoped for early 2021. The company and the federal government are investing more than $1 billion in the vaccine effort.
Leukocare: Munich-based biotech firm is partnering with Rome-based ReiThera and Belgian biomanufacturing startup Univercells to work on a Covid-19 vaccine; clinical trials are scheduled to begin in Italy in this summer.
Medicago: Quebec City-based biotech company received more than $7 million from the Canadian and Quebec governments to fund development of its Covid-19 vaccine. On May 14, the firm announced positive results from animal trials of its vaccine candidate, with phase one clinical trials in humans expected to begin in the summer.
Moderna: Massachusetts biotech company, led by billionaire CEO Stéphane Bancel, was the first to begin human trials of its vaccine — on March 16 in Seattle — and could deploy it to health workers for emergency use by the fall, according to Bancel. On April 16, the company announced a grant of up to $483 million from the Department of Health and Human Services to accelerate development of the vaccine; on May 12, the FDA granted fast track designation to Moderna’s vaccine. The company announced positive results from phase one human trials of its vaccine candidate on May 18, showing that all participants developed antibodies to Covid-19 after taking the vaccine.
Novavax: Maryland-based vaccine maker received up to $388 million in funding from CEPI on May 11 — on top of $4 million it obtained on March 10 — to accelerate development of its vaccine candidates. On April 8, the firm announcedit would begin human trials of its vaccine in Australia in mid-May, with preliminary results expected in July. The firm announced it had begun human trials of its vaccine on May 25 in Australia, with preliminary results expected in July.
Sanofi: French medical firm is working with the federal government and Massachusetts-based Translate Bio to expedite its coronavirus vaccine, using technology previously used to develop one for SARS.
Shionogi: The publicly traded Japanese pharmaceutical company is working on a Covid-19 vaccine with the country’s Agency for Medical Research and Development; the firm is also collaborating with researchers at the Hokkaido University Research Center for Zoonosis Control on potential treatments for the disease, with plans to start clinical trials in late 2020.
Sinovac Biotech: Beijing-based biotech firm received approval from the Chinese government to begin human trials of its Covid-19 vaccine on April 14.
SK Group: South Korean conglomerate’s pharmaceutical arm, SK Bioscience, is conducting animal trials of its Covid-19 vaccine.
Sorrento Therapeutics: San Diego-based biotech firm is teaming up with Cambridge, MA gene therapy company SmartPharm Therapeutics to develop a gene-encoded Covid-19 vaccine; it’s also working with Chinese drugmaker Mabpharm on a fusion protein treatment for the disease.
Takis Biotech: Italian startup with just 25 employees is developing a vaccine with Stony Brook, New York-based Applied DNA Sciences, with plans to begin human trials before the end of the year; on April 10, the company announced“extremely positive” results from animal trials for all five of its vaccine candidates.
Themis Bioscience: Austrian biotech firm is part of a group, with the Institut Pasteur and the University of Pittsburgh, which received $4.9 million in initial funding from CEPI to build a Covid-19 vaccine modeled on the vaccine for measles. On May 26, the firm was acquired by pharmaceutical titan Merck for an undisclosed amount.
Tonix Pharmaceuticals: New York-based pharma outfit is researching a potential Covid-19 vaccine based on the virus that causes horsepox.
Vaxart: San Francisco vaccine manufacturer Vaxart is working with Emergent Biosolutions to develop and manufacture an oral vaccine that can be taken as a tablet.
Vaxil: Israeli biotech startup began preclinical trials for its Covid-19 vaccine candidate.
Vaxine Pty Ltd: Adelaide, Australia-based biotech company is working with researchers at nearby Flinders University to develop a vaccine for Covid-19.
VBI Vaccines: Massachusetts-based vaccine developer is collaborating with the National Research Council of Canada on a “pan-coronavirus” vaccine, which would target Covid-19 as well as SARS and Middle East respiratory syndrome, or MERS.
Protective Equipment And Sanitizer:
Anheuser-Busch InBev: The world’s largest beer company is making more than one million bottles of hand sanitizer from surplus alcohol at its breweries around the world.
Ansell: Australian protective equipment maker is expanding production capacity to meet higher demand for its biohazard suits and gloves.
Aria Designs: North Carolina furniture manufacturer received financing from CIT Group to procure millions of N95 surgical masks with its international suppliers.
Bacardi: The Bermuda-based spirits giant converted production at nine production facilities in Mexico, France, England, Italy, Scotland, Puerto Rico and the continental U.S. to make hand sanitizer.
Barbour: On April 15, the British fashion brand announced its plans to produce 23,000 medical gowns over three weeks, with an initial run of 7,000 expected by April 19.
Bauer Hockey: Canadian ice hockey equipment maker is partnering with Liverpool, New York lacrosse equipment manufacturer Cascade Maverik Lacrosse to produce face shields at factories in Quebec and New York.
Bulgari: The Italian luxury jeweler is manufacturing hand sanitizer with its fragrances partner, ICR, with plans to make hundreds of thousands of bottles by May.
Calzedonia Group: Italian retail clothing group, owned by billionaire Sandro Veronesi, converted production at several plants in Italy and Croatia to manufacture masks and medical gowns, with initial production of 10,000 masks a day.
Cantabria Labs: Spanish health products and cosmetics firm convertedproduction at one of its factories to make hand sanitizer.
Charoen Popkhand Group: Thai animal feed and livestock producer, chaired by billionaire Dhanin Chearavanont, invested $3 million in a Bangkok factory to produce 100,000 surgical masks a day; the group is also delivering free food to patients and staff at more than 40 Thai hospitals.
Colgate: Consumer goods maker is coordinating with the WHO to make 25 million soap bars at five factories on three continents, which will be donated to authorities lacking supplies in the fight against Covid-19.
Consomed: Tunisian mask and medical equipment maker put all of its workers, more than 70% of which are reportedly women, on quarantine inside the company’s Kairouan factory to maximize production of protective gear.
Decathlon: Sporting goods empire founded by French billionaire Michel Leclercq partnered with Isinnova, a small engineering and design firm based in Italy, to convert snorkeling masks into respirators.
Diageo: The maker of Johnnie Walker whisky and Smirnoff vodka donated two million liters of ethyl alcohol, a byproduct of the distillation process, to hand sanitizer manufacturers.
Dickies: Fort Worth, Texas-based apparel brand is working with its parent company VF Corporation to convert plants in Mexico and Honduras to make FDA-approved isolation gowns; 50,000 are expected in May, with plans to ramp up production to 675,000 per month by June and 3.4 million by September.
ExxonMobil: Oil & gas multinational is partnering with the Atlanta-based Global Center for Medical Innovation to coordinate the manufacturing of face shields and masks with refillable filter cartridges; prototypes are awaiting FDA approval, with plans to eventually produce up to 40,000 masks and cartridges per hour.
Fiat Chrysler Automobiles: The multinational automaker announced on March 23 it would begin installing capacity to produce masks, which will be initially distributed in the U.S., Canada and Mexico.
Fippi: Italian diapers producer worked with the Lombardy region and the Polytechnic University of Milan to convert its factory to make up to 900,000 masks a day, which will go to frontline health workers facing a devastatingoutbreak in the region.
GelPro: Austin-based maker of floor mats shifted part of its factory in Waco to produce face shields, with the first batch of 500 shields donated to healthcare workers at the field hospital set up in New York City’s Central Park.
González Byass: Spanish spirits maker made three of its facilities and distilleries available to public health authorities for the production of hand sanitizer.
GVS: Family-owned Italian company is hiring more workers to expand production of ventilator filters and biohazard antivirus masks, destined for hospitals in Italy, the U.S. and China.
HP: The tech multinational is using its 3D printing centers in four cities — Barcelona, San Diego, Corvallis, Oregon and Vancouver, Washington — to make masks, face shields and ventilator parts.
IKEA: Swedish furniture retailer is reportedly working with suppliers to increase production of masks, hand sanitizers, visors and aprons; the company also openeda drive-through Covid-19 testing facility with the UK’s National Health Service (NHS) at its store in the Wembley area of London.
Ineos: Billionaire James Ratcliffe’s chemical powerhouse Ineos is building a new hand sanitizer plant in the UK — which will be ready in just 10 days — to produce a million bottles a month, and plans to build another in Germany.
Jenco Productions: San Bernardino, California-based printing firm shiftedproduction on April 20 to start making more than 100,000 face shields a day.
Jockey: Wisconsin-based underwear maker is working with McDonough, Georgia-based medical products manufacturer Encompass Group to make up to 50,000 isolation gowns a week.
Massaflex: Italian mattress maker converted all production at its factory in Tuscany to make masks.
Medline: Northfield, Illinois family-owned manufacturer is ramping up production to supply medical masks, biohazard bags, surgical clothing and disinfectants to hospitals across the United States.
Menarini: Pharma firm, owned by Italian billionaire Massimiliana Landini Aleotti and her three children, converted a production line at its Florence factory to make disinfectant gel that will be distributed free of charge to Italy’s civil protection agency. The company is also working with Singapore-based Credo Diagnostics to distribute Credo’s new 20-minute coronavirus testing kit, which has been approved by European regulators.
Miroglio Group: Italian fashion group converted production at its factories in the northwestern Italian region of Piedmont to make up to 100,000 masks a day.
Nike: Sportswear giant founded by billionaire Phil Knight is manufacturing face shields and respirator lenses in partnership with Oregon Health & Science University; the products are being donated to healthcare workers in Oregon, Boston, Memphis, St. Louis and Cleveland.
O.C. Tanner: Salt Lake City, Utah cloud-based software and employee recognition firm converted part of its manufacturing — which normally makes custom awards and trophies — to make hundreds of masks and ventilator parts, with an initial batch donated to the University of Utah Health hospital.
Parafix: British adhesive materials maker converted production to manufacture 25,000 face shields a day, delivering them to NHS hospitals in Sussex and Bristol.
Pernod Ricard: French spirit maker’s U.S. branch is producing hand sanitizer at four distilleries in Arkansas, Kentucky, Texas and West Virginia.
Prada: On March 23, the luxury fashion empire — led by billionaire couple Miuccia Prada and Patrizio Bertelli — announced it would convert production at its factory in Perugia to make 80,000 medical overalls and 110,000 masks for healthcare workers in the Tuscany region.
Procter & Gamble: Consumer goods giant is installing new production lines at five factories to make 45,000 liters of hand sanitizer a week; the company is also making face masks in China and will soon begin production at plants in North America, Europe, Africa and elsewhere in Asia.
Quicken Loans: Detroit-based mortgage lender, founded by billionaire Dan Gilbert, is planning to produce 500,000 masks a week in a partnership with Dearborn-based apparel firm Carhartt and the Detroit-area Industrial Sewing and Innovation Center.
Reliance Industries: Billionaire Mukesh Ambani’s sprawling conglomerate is ramping up production of face masks to 100,000 a day, as well as producing protective suits and garments for India’s health workers; the company’s Reliance Foundation has set up Covid-19 wards in Mumbai and Lodhivali.
San Miguel Corporation: Philippine beermaker, led by billionaire Ramon Ang, is producing up to 100,000 liters of rubbing alcohol a day at facilities run by its subsidiary Ginebra San Miguel Inc.; it has donated over 120,000 liters of the product to Philippine hospitals, government agencies and the National Police.
Seamus Golf: Beaverton, Oregon-based golf equipment maker convertedproduction to make more than 1,500 masks a day.
Siemens: German multinational’s U.S. unit is working with Georgia Tech to produce up 2,500 face shields a day for hospitals in the Atlanta area; the company also opened up its global 3D printing network for designers and suppliers of medical devices around the world, free of charge.
Stanley Black & Decker: Connecticut-based manufacturing giant is 3D-printing face shields and working with hospitals, universities and other manufacturers to develop new mask and respirator technologies.
Starkey Hearing Technologies: Minnesota-based hearing aid maker, owned by billionaire Bill Austin, is reportedly partnering with custom components manufacturer Lakeview Industries to make about 150,000 face shields a day.
Top Glove: Malaysian medical glove maker, one of the world’s largest, is ramping up production and has donated more than 5 million gloves to authorities in China and Malaysia.
Volkswagen: German automaker’s U.S. arm is working with its fabric supplier, the French auto parts maker Faurecia, to convert production at a Faurecia plant in Mexico to make masks and gowns; an initial shipment of 70,000 masks and 5,000 gowns will be distributed to hospitals in the New York area. In Europe, the group’s various companies — including Lamborghini, SEAT, and Škoda — have been 3D printing face shields and masks for authorities in the Czech Republic, Germany, Italy and Spain.
Voodoo Manufacturing: Brooklyn-based 3D printing firm repurposed its manufacturing facility to produce face shields and testing swabs.
Ventilators And Medical Devices:
BAE Systems: British aerospace company is part of the Ventilator Challenge UK Consortium.
Bloom Energy: San Jose, California-based fuel cell maker is refurbishingunused and out-of-warranty ventilators in a partnership with Philadelphia-based appliance distributor Almo Corporation, which will then ship them to state agencies and hospitals across the U.S.
BreathDirect: Long Beach-based startup was recently established by Darren Saravis, CEO of medical device firm Nectar, to quickly produce 3,500 ventilators a week by May at $10,000 each.
Dyson: British billionaire James Dyson announced in March that his vacuum cleaner and hand dryer firm would start designing and making 10,000 ventilators, with more to come; the order was later canceled by the British government.
Ford: Auto giant is working with 3M and General Electric’s healthcare unit to make ventilators, respirators and face shields at its manufacturing sites; Ford and GE Healthcare announced on March 30 that the companies would produce50,000 ventilators by July 8 with plans to increase production to 30,000 a month. The company is also partnering with healthcare giant Thermo Fisher Scientific to scale up production of Covid-19 testing kits.
General Motors: The auto titan announced on March 27 it would start building ventilators at its Kokomo, Indiana plant in a partnership with medical device maker Ventec Life Systems, as well as producing masks at a factory in Michigan. Hours later, President Donald Trump invoked the Defense Production Act to compel GM to “accept, perform and prioritize federal contracts for ventilators.” On April 8, the company was awarded a $489.4 million contract with the HHS to to provide 30,000 ventilators by the end of August.
GKN Aerospace: British aerospace firm is a member of the Ventilator Challenge UK Consortium.
Hill-Rom: Batesville, Indiana healthcare equipment manufacturer more than doubled its production of ventilators, ICU beds and diagnostic monitors. The firm was also included in U.S. President Donald Trump’s order under the Defense Production Act, which will help the company “secure the supplies they need to build ventilators needed to defeat the virus.”
Inspiration Healthcare: British medical devices maker is part of the Ventilator Challenge UK Consortium.
Mahindra Group: Mumbai-based conglomerate, owned by billionaire Anand Mahindra and his family, announced on March 22 it would begin producing ventilators at plants in India, reportedly pricing them at less than $100 each. The company has produced at least 250,000 face shields and 34,000 liters of disinfectants as of May 15, and also converted 50 resorts to temporary care facilities for Covid-19 patients.
Malvestio: Italian maker of ICU and hospital beds is ramping up production by 30-40% to meet a surge in demand for its beds from hospitals in Italy.
Medtronic: Minnesota-based medical device maker publicly shared the design specifications for its basic ventilator model, with the goal of helping other companies quickly manufacture ventilators. The company was also included in President Trump’s order under the Defense Production Act.
Meggitt: British aerospace and defense components maker is a member of the Ventilator Challenge UK Consortium.
Penlon: Oxford-based medical device maker is part of the Ventilator Challenge UK Consortium.
Philips: The Dutch multinational is doubling production of pulmonary ventilators, with plans to quadruple it by the third quarter of 2020. The company was also included in President Trump’s order under the Defense Production Act; on April 6, the HHS announced a $467 million contract with Philips to produce 2,500 ventilators by the end of May and 43,000 by the end of the year.
ResMed: San Diego-based medical equipment maker is planning to more than double its production of ventilators and increase output of masks more than tenfold. The firm was also included in President Trump’s order under the Defense Production Act.
Rolls-Royce: The luxury carmaker is a member of the Ventilator Challenge UK Consortium.
SIARE Engineering: Italy’s largest ventilator producer enlisted the help of Italian army technicians and employees from Fiat Chrysler and Ferrari to ramp up production.
Smiths Group: British engineering firm is part of the Ventilator Challenge UK Consortium.
Thales Group: French aerospace multinational is a member of the Ventilator Challenge UK Consortium.
Ultra Electronics: British defense systems provider is part of the Ventilator Challenge UK Consortium.
Virgin Galactic: The space tourism firm, launched by billionaire Richard Branson, is working with NASA under the Space Act Agreement to build a breathing assistance device less invasive than ventilators to help patients fighting Covid-19.
Xerox: Copying giant is partnering with Sacramento-based medical device manufacturer Vortran to scale up its production of ventilators to 40,000 a month in April and then between 150,000 and 200,000 a month by June.
Supporting Healthcare Workers And First Responders:
Airbnb: The peer-to-peer home rental company, cofounded by billionaires Brian Chesky, Nathan Blecharczyk and Joe Gebbia, is providing housing for 100,000 Covid-19 responders in homes volunteered by Airbnb hosts around the world.
Airbus: European airplane maker is partnering with San Rafael, California-based neurotechnology firm Koniku to develop technologies that could help airport security identify biological hazards by detecting the odor of viruses such as Covid-19, with testing planned in the fourth quarter of 2020.
Alibaba: E-commerce titan, cofounded by billionaire Jack Ma, launched the Global MediXchange for Combating Covid-19, an online platform to help doctors around the world share expertise and best practices to fight the Covid-19 pandemic. The company’s mobile payment arm, Alipay, has deployed Health Code, a color-coded health monitoring system developed by the Chinese government, which gives users a red, green or yellow code based on their travel history and potential exposure to the virus.
Anaplan: San Francisco-based planning software firm is providing free access to its platform for 90 days to nonprofits, government agencies, pharmaceutical companies, academic institutions, healthcare providers and others on the Covid-19 frontlines.
Apple: Cupertino tech giant is partnering with Google to use Bluetooth technology and downloadable apps to help public health authorities conduct contact tracing of Covid-19 patients; the states of Alabama, North Dakota and South Carolina and countries including Ireland, Germany, Italy, Switzerland and the Netherlands have signed on to use the app technology, with Swiss researchers launching the first prototype on May 25.
Boston Dynamics: Waltham, Massachusetts robotics firm, owned by Japanese billionaire Masayoshi Son’s SoftBank Group, sent its robot dog Spot to help staff at Boston’s Brigham and Women’s Hospital receive patients, deploy triage tents and conduct telehealth visits.
EverBlock Systems: Modular building block maker built a temporary hospital to treat Covid-19 patients, using its plastic building blocks and wall units, at the Ernest N. Morial Convention Center in New Orleans.
Facebook: Billionaire Mark Zuckerberg’s social media giant is offering its disease prevention maps and social connectedness index — two data-based tools that measure Facebook users’ movements and map their friends networks — to nonprofits and researchers fighting Covid-19.
First Due: Emergency response platform partnered with the International Association of Fire Chiefs and mapping software firm Esri, founded by billionaire Jack Dangermond, to build a national Covid-19 self-reporting system that will provide self-reported health data to first responders.
GlobeKeeper: Tel Aviv-based security app developer worked with Israel’s Health Ministry to launch a voluntary tracking app which allows users to report their exposure to Covid-19; the company is reportedly rolling out its own coronavirus-tracking app, named SAFE, in India next week with plans to expand to other countries.
GoPuff: Late-night delivery app popular with college students is pivoting to deliver essential supplies to healthcare workers at hospitals in Chicago, Philadelphia and Washington D.C.
Headspace: The meditation and mindfulness app is granting free access to its premium offering, Headspace Plus, to healthcare workers in the U.S. through the end of 2020.
Hyundai: Korean automaker is opening drive-through Covid-19 testing centers at 11 children’s hospitals in ten states and Washington, D.C. as well as providing $2.2 million in grants.
Inditex: The Spanish fast fashion giant behind Zara and other brands, majority-owned by billionaire Amancio Ortega, is making its logistics and procurement network available to the Spanish government to coordinate supply of materials needed to make masks, gloves, face shields and other protective equipment.
Intel: Tech giant cofounded by billionaire Gordon Moore is investing $40 million in a Covid-19 response and readiness initiative, which will help healthcare manufacturers use Intel’s AI and cloud computing tools to identify solutions to treat Covid-19.
Manna Aero: Irish drone food delivery startup is launching a trial of the world’s first drone delivery service to bring groceries and medicines to vulnerable people; the trial will begin in the small Irish village of Moneygall.
Medallia: San Francisco-based cloud computing firm offered its crowdsourcing platform free of charge to nonprofits for six months, with partners including Oxfam and the International Committee of the Red Cross.
NeuroFlow: Philadelphia-based mental health startup built a free online tool that helps users check their symptoms to see if they should get tested for Covid-19, as well as screening for signs of anxiety and providing mental health resources.
Nuro: Driverless vehicle startup is using its unmanned R2 vehicles to deliver essential supplies to doctors and nurses at two temporary Covid-19 hospitals in Sacramento and San Mateo, California.
Palantir: Big data firm, cofounded and chaired by billionaire Peter Thiel, is working with the U.S. Centers for Disease Control and the HHS, as well as the UK’s NHS, on coronavirus-tracking software based on its data gathering and analysis technology platform, Palantir Foundry.
Rave Mobile Safety: Massachusetts-based safety collaboration platform is providing its Smart911 service, which allows users to provide information to authorities by creating profiles on a mobile app, free of charge; the platform is being used by first responders tracking Covid-19 cases in New Orleans, Chicago, Long Island and Arkansas.
Speetar: Libyan telehealth platform, which helps doctors in diasporas treat patients in their countries of origin, is working with the Libyan Ministry of Health to track and treat Covid-19 patients in the country; the company is also in talks to expand to Egypt and Pakistan.
Tencent: Internet giant chaired by billionaire Ma Huateng reportedly launched a mini-app named Fuxuema, embedded within its popular messaging app WeChat, which allows students returning to school to receive a color-based QR code identifying their Covid-19 health status. The company had already worked with the Chinese government to deploy a broader color-coded system through WeChat.
UiPath: AI software startup, founded by billionaire Daniel Dines, is offering its robotic process automation software for free to healthcare organizations and hospitals, freeing up nurses and staff to focus more on patients.
UnitedHealth: The health insurance giant is teaming up with Microsoft to launch an app called ProtectWell, which is designed to help companies get employees back work. The app will have a simple self-screening tool developed based on CDC guidelines, information on how to follow the proper protocols and more.
Vista Land Group: Philippine property developer chaired by billionaire Manuel Villar — the country’s richest person — worked with construction firm EEI and the Philippine Department of Public Works and Highways to build a temporary hospital at the Philippine International Convention Center in Manila.